Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04969939 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT04969939: Completed Phase 2 study, sponsored by Novo Nordisk A/S.
NCT04969939 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04969939, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show participants how. The study will last for about 26 weeks. Participants will have 17 visits at the clinic with the study doctor. At 4 of the clinic visits participants cannot eat and drink (water is allowed until 2 hours prior to the visit) for 8 hours before the visit.Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period. Women who are able to become pregnant can participate if they agree to use contraception during the study.
Primary Outcome
A TEAE is defined as an event that has onset after administration of trial product and no later than the follow-up visit or is present before trial product administration and increases in after the first dose of trial product and no later than the follow-up visit.
Interventions
- DRUG Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
- DRUG Semaglutide 2.4 mg and placebo 2.0 mg
- DRUG Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
- DRUG Semaglutide 2.4 mg and placebo 1.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 2 |
What the finished NCT04969939 record still lists
NCT04969939 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 4 interventions - of which Semaglutide 2.4 mg and NNC0165-1875 2.0 mg is the first listed.
NCT04969939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04969939 about?
NCT04969939 is a clinical study titled "A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity". The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same ...
What is the current status of trial NCT04969939?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2021-07-15. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT04969939?
The interventions under investigation include: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg (DRUG), Semaglutide 2.4 mg and placebo 2.0 mg (DRUG), Semaglutide 2.4 mg and NNC0165-1875 1.0 mg (DRUG), Semaglutide 2.4 mg and placebo 1.0 mg (DRUG).
Who is sponsoring clinical trial NCT04969939?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04969939's enrollment target sits among peer trials
120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI